Pardes Biosciences Past Performance
Past criteria checks 0/6
Pardes Biosciences's earnings have been declining at an average annual rate of -67.8%, while the Biotechs industry saw earnings growing at 31.6% annually.
Key information
-67.8%
Earnings growth rate
49.0%
EPS growth rate
| Biotechs Industry Growth | 32.1% |
| Revenue growth rate | n/a |
| Return on equity | -56.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20
We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Earnings and Revenue History
Quality Earnings: PRDS is currently unprofitable.
Growing Profit Margin: PRDS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PRDS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PRDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Return on Equity
High ROE: PRDS has a negative Return on Equity (-56.46%), as it is currently unprofitable.